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    In 2013, the CDC published “Antibiotic Resistance Threats in the United States” in 
which Clostridium difficile was recognized as an urgent threat.  As a result, a 50% 
decrease in Clostridium difficile infection (CDI) incidence and a 20% decrease in the 
use of inpatient antibiotics has been mandated by 2020. CDI carries many 
implications ranging from increased morbidity and mortality to longer length of 
hospital stay.  
    Typical risk factors associated with CDI include elderly age (> 64y), increased 
length of stay, and debilitation. Certain medications, such as chemotherapy, 
antibiotics and proton pump inhibitors (PPI), may also predispose patients to CDI.  Of 
these risk factors,  antibiotics have been recognized as the most important risk factor 
for CDI. Although all classes have been associated with CDI, clindamycin, third-
generation cephalosporins and fluoroquinolones pose the highest risk. As a result, 
pharmacists are at an ideal position to address the multiple medication centered risk 
factors. 
 
•Primary objectives: identify prescribing patterns of antibiotics and PPI in order to 
perform pharmacist led interventions targeting modifiable risk factors 
•Secondary objective: promote antimicrobial stewardship practices (ASP) and 
appropriate PPI use in patients at risk for HA-CDI 
•This study was institutional review board (IRB) approved  
•Biphasic study, including patients ≥18 years old  
•Phase I: retrospective chart review of HA-CDI patients from 01/14 – 06/15  
•Phase II: prospective review of interventions targeting HA-CDI prevention 
from 11/15 – 03/16  
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infections: interrupted time-series analysis. Journal of Hospital Infection. 2015. 1-7. 
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2009. 62 (2) 142-147. 
Antimicrobials and PPIs are the most common predisposing factors for CDI, and as a 
result, pharmacists are in an ideal position in order to target medication related risk 
factors. By implementing practices, such ASP and PPI de-escalation, into daily 
responsibilities not only are we able to prevent HA - CDI and other medication 
related side effects, but also contribute to significant cost savings.  
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• Retrospective data collection demonstrated that risk factors present in the 151 
patients diagnosed with HA-CDI were consistent with those outlined in the literature 
(Table 1) 
• The majority of patients were female, with average age of 70 years 
• One-third of patients were either on tube feeds or chemotherapy  
• 85 % of patients were on antibiotics 
• 66 % of patients were on a PPI 
• 64 % of patients were on antibiotics and gastric acid suppression 
• During the prospective phase of the study, 183 interventions were made 
• The majority of patients were female, ≥ 65 years with an average length of 
stay (LOS) of 11 days 
• None of the patients in the pharmacist led intervention group vs 7 patients in 
the control group developed HA-CDI 
• 51 PPI interventions were made , of these 37 were discontinuations, and 17 were 
de-escalations to a histamine-2 blocker 
• There was no significant  difference between intervention or control groups 
• Nobody in the intervention group developed HA-CDI versus 2 patients in the 
control group 
• 132 ASP interventions were made (Tables 3), of these the majority were 
ceftriaxone, levaquin and vancomycin interventions 
• The ceftriaxone intervention population had a statistically significantly lower 
amount of patients on tube feeds versus the control population 
• The levofloxacin intervention population  had a statistically higher amount of 
elderly patients versus the control population 
• There was no significant differences in the levaquin  
• Interventions performed were associated with an approximate cost savings of 
$19,780.88. 
All authors of this presentation have nothing to disclose concerning possible financial 
or personal relationships with commercial entities that may have direct or indirect 
interest in the subject matter of this presentation 
Table 1: Clinical Characteristics of 
HA-CDI Patients 
Conclusion 
Results Background 
References 
Disclosures 
Methods 
Objectives 
Characteristic  n = 151 
Age - average (range)  
70 yrs  
(18 – 105)  
Female gender - n (%)  82 (54)  
Days between symptom onset  - 
average (range)  
12  
(3 – 185)  
Tube feeds - n (%)  38 (25)  
Chemotherapy - n (%)  41 (27)  
Gastric acid suppression - n (%)  
PPI 
H2B  
100 (66)  
15 (10)  
Antimicrobials - n (%) 
Piperacillin/tazobactam  
Vancomycin  
Levofloxacin  
Ceftriaxone  
Ciprofloxacin 
Clindamycin  
129 (85) 
55 (43) 
30 (23) 
32 (25) 
29 (22) 
1 (1) 
2 (2)  
Gastric acid suppression and 
antibiotics – n (%)  
96 (64)  
Table 2: Subgroup Population 
Analysis: PPI interventions 
Control 
(n=51) 
Intervention 
(n=51)  
Age ≥ 65 - (%) 59  75  
Female gender-(%)  59  55  
Tube feed - (%)  14  8  
LOS - average 
(range)  
8  
(2-49)  
9  
(2-54)  
On antibiotics - (%)  61  59  
HA-CDI-tested- (%)  8  10  
HA-CDI - (%)  2  0  
Table 3: Subgroup Population Analysis: ASP Interventions 
 Ceftriaxone (n=39)  Levofloxacin (n=17)  Vancomycin (n=56)  
Control  Intervention  Control  Intervention  Control Intervention  
Age ≥ 65 - (%) 67  67  35*  63*  54  63  
Female gender-(%)  59  64  59  59  45  59  
Tube feed - (%)  10*  0*  6  18  11  14  
LOS - average 
(range)  
10 
 (2-46)  
11 
(2-107)  
10 
(2-48)  
14    
(2-39)  
12 
(2-45)  
12 
(2-53)  
Concomitant 
antibiotics - (%)  
54  44  35  59  80  88  
PPI - (%)  51  39  47  59  52  38  
HA-CDI-tested-(%)  26  10  24  6  23  13  
HA-CDI - (%)  3  0  0  0  2  0  
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• CDI: Clostridium difficile infection
• CDC: Centers for Disease Control and Prevention
• HA-CDI: Hospital acquired - Clostridium difficile infection
• BHM: Baptist Hospital of Miami
• ASP: Antimicrobial stewardship program
• PPI: Proton-pump inhibitor
• H2B: Histamine 2 blocker
• LOS: Length of stay
• Recognize CDI as a CDC national threat
• Identify risk factors for HA - CDI at BHM
• Review pharmacy driven interventions to  CDI
• Assess pharmacy interventions cost savings
2013
‘Antibiotic Resistance Threats in the U.S.’ 
released by CDC
2015
‘National Action Plan to Combat Antibiotic-
Resistant Bacteria’ released by White House
2020 Goals: 20 %  antibiotics, 50%  CDI
CDC.2013
• Clinically significant diarrhea or toxic megacolon
without other etiology that meets one or both of the 
following criteria 
– Positive stool sample
– Pseudomembranous colitis
• Symptom onset > 3 days after admission
• National average: 2.8 - 9.3 per 10,000 patient days
Infection Control and Hospital 
Epidemiology. 2010. 31 (5) 430-455.
5/2/2016
2
Age ≥ 65
Female
LOS
Severe illness
Tube feeds
Chemotherapy
GI surgery
Non-
modifiable
Antibiotics
Gastric acid suppression (PPI)
Modifiable
CID. 2008. 46. S19-31. 
CID. 2004: 38: 646-8.
Age - average (range) 70 yrs (18 – 105)
Female gender - n (%) 82 (54)
Days between symptom onset - average (range) 12 (3 – 185)
Tube feeds - n (%) 38 (25)
Chemotherapy - n (%) 41 (27)
Gastric acid suppression - n (%)
PPI
H2B
100 (66)
15 (10)
Antimicrobials- n (%)
Piperacillin/tazobactam
Vancomycin
Levofloxacin
Ceftriaxone
Ciprofloxacin
Clindamycin
129 (85)
55 (43)
30 (23)
32 (25)
29 (22)
1 (1)
2 (2)
Gastric acid suppression and antibiotics – n (%) 96 (64)
Characteristic                                                           n = 151
• Identify prescribing patterns of antimicrobials 
and PPIs among patients
• Implement pharmacist led initiative 
– Target high risk meds
– Promote ASP practices
– Discontinue unwarranted PPIs
– Document Pharmacist interventions 
• IRB approved 
• Single center prospective cohort study 
– November 2015 to March 2016
• Inclusion 
– Adults (≥ 18 yrs) 
– Pharmacist - led interventions
• Asses pharmacist-led interventions
• Evaluate the pharmacist’s impact in targeting 
modifiable risk factors to prevent HA-CDI
• Identify cost savings associated with 
interventions utilizing Theradoc®
Characteristic n = 183
Age ≥ 65 - n (%) 127 (69)
Female gender - n (%) 116 (63)
LOS - average (range) 11 days (2 - 107)
Tube feed - n (%) 21 (11)
Concomitant antibiotic use - n (%) 87 (48)
Interventions - n
PPI
Vancomycin
Ceftriaxone
Levofloxacin
Piperacillin/tazobactam
Unasyn/Augmentin
Carbapenems
Clindamycin
Aztreonam
51
56
39
17
10
3
3
2
2
HA - CDI incidence 0
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*p ≤ 0.05
PPI
(n=51)
Control Intervention
Age ≥ 65 - (%) 59 75
Female gender-(%) 59 55
Tube feed - (%) 14 8
LOS - average (range)
8 
(2-49)
9 
(2-54)
On antibiotics - (%) 61 59
HA-CDI-tested- (%) 8 10
HA-CDI - (%) 2 0
*p ≤ 0.05
Ceftriaxone
(n=39)
Levofloxacin
(n=17)
Vancomycin
(n=56)
Control Intervention Control Intervention Control Intervention
Age ≥ 65 - (%) 67 67 35* 63* 54 63
Female gender-(%) 59 64 59 59 45 59
Tube feed - (%) 10* 0* 6 18 11 14
LOS - average 
(range)
10
(2-46)
11
(2-107)
10
(2-48)
14   
(2-39)
12
(2-45)
12
(2-53)
Concomitant 
antibiotics - (%) 54 44 35 59 80 88
PPI - (%) 51 39 47 59 52 38
HA-CDI-tested- (%) 26 10 24 6 23 13
HA-CDI - (%) 3 0 0 0 2 0
ASP Interventions (n=132)
Intervention type Number of interventions Associated cost-savings
Bug-drug mismatch 7 $525.00
De-escalation 71 $6,390.00
Duplication of coverage 4 $360.00
Discontinue antibiotics 40 $3,000.00
Antibiotics not indicated 10 $750.00
Total savings - antibiotic interventions = $11,025.00
PPI Interventions (n=51)
Intervention type Number of interventions Associated cost-savings
Discontinuation of PPI 34 $7,480.88
De-escalation of PPI 17 $1,275.00
Total savings – PPI interventions = $8,755.88
Estimated savings: $19,780.88
• Strengths
– Study design: prospective, control matched
– Proactive approach utilizing different interventions
• Limitations
– Small sample size  multiple confounding factors
– Constraints: time, formulary
– Bias: attrition, selection, information
• Future direction
– Expansion of BHM ASP practices
– Stress ulcer prophylaxis protocol
• Antimicrobials and PPIs are the most common 
predisposing factors for CDI
• Pharmacists play a vital role in CDI prevention
• ASP reduces the incidence of CDI
• Preventative CDI interventions  cost savings
• Co-investigators
– Jenny Martinez, Pharm. D., BCPS-AQ ID 
– Heidi Clarke, BCCCP
• Infection Control Department 
– Barbara Russell, RN, MPH, CIC 
– Carol Covington, RN
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Which three antibiotics or antibiotic classes are 
associated with the highest risk for CDI ? 
– Fluoroquinolones
– Clindamycin
– 3rd generation cephalosporins
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